Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma
Condition(s):Metastatic Pancreatic AdenocarcinomaLast Updated:September 18, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Metastatic Pancreatic AdenocarcinomaLast Updated:September 18, 2023Recruiting
Condition(s):Metastatic Pancreatic AdenocarcinomaLast Updated:January 29, 2024Recruiting
Condition(s):Metastatic Pancreatic AdenocarcinomaLast Updated:May 4, 2016Completed
Condition(s):Metastatic Pancreatic AdenocarcinomaLast Updated:October 3, 2023Completed
Condition(s):Metastatic Pancreatic AdenocarcinomaLast Updated:December 23, 2022Completed
Condition(s):Metastatic Pancreatic AdenocarcinomaLast Updated:January 17, 2024Recruiting
Condition(s):Metastatic Pancreatic AdenocarcinomaLast Updated:July 2, 2017Completed
Condition(s):Metastatic Pancreatic AdenocarcinomaLast Updated:December 31, 2020Completed
Condition(s):Metastatic Pancreatic AdenocarcinomaLast Updated:December 30, 2020Completed
Condition(s):Metastatic Pancreatic AdenocarcinomaLast Updated:January 17, 2024Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.